182 related articles for article (PubMed ID: 19431095)
21. Soluble epidermal growth factor receptor acridinium-linked immunosorbent assay.
Lafky JM; Baron AT; Maihle NJ
Methods Mol Biol; 2006; 327():39-47. PubMed ID: 16780211
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
23. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
Petrelli F; Cabiddu M; Ghilardi M; Barni S
Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
[TBL] [Abstract][Full Text] [Related]
24. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
25. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
26. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
Dinh P; Harnett P; Piccart-Gebhart MJ; Awada A
Crit Rev Oncol Hematol; 2008 Aug; 67(2):103-12. PubMed ID: 18342536
[TBL] [Abstract][Full Text] [Related]
27. Emerging targeted therapies for breast cancer.
Arnedos M; Seidman AD
Hematol Oncol Clin North Am; 2007 Apr; 21(2):321-40. PubMed ID: 17512452
[TBL] [Abstract][Full Text] [Related]
28. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
Krause M; Baumann M
Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
[TBL] [Abstract][Full Text] [Related]
29. Targeting signaling pathways in ovarian cancer.
Reibenwein J; Krainer M
Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapies in breast cancer: where are we now?
Di Cosimo S; Baselga J
Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
[TBL] [Abstract][Full Text] [Related]
31. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
Riesterer O; Milas L; Ang KK
J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456
[TBL] [Abstract][Full Text] [Related]
32. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.
Gadducci A; Cosio S; Tana R; Genazzani AR
Crit Rev Oncol Hematol; 2009 Jan; 69(1):12-27. PubMed ID: 18595727
[TBL] [Abstract][Full Text] [Related]
33. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
Abu-Khalaf MM; Harris L
Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
[No Abstract] [Full Text] [Related]
34. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
35. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
36. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking.
Madshus IH; Stang E
J Cell Sci; 2009 Oct; 122(Pt 19):3433-9. PubMed ID: 19759283
[TBL] [Abstract][Full Text] [Related]
37. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
38. [Lung cancer].
Ayabe E; Kaira K; Yamamoto N
Gan To Kagaku Ryoho; 2009 Jan; 36(1):21-5. PubMed ID: 19151561
[TBL] [Abstract][Full Text] [Related]
39. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer.
Cho WC
Biomed Pharmacother; 2007 Oct; 61(9):515-9. PubMed ID: 17913444
[TBL] [Abstract][Full Text] [Related]
40. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
Bertenshaw GP; Yip P; Seshaiah P; Zhao J; Chen TH; Wiggins WS; Mapes JP; Mansfield BC
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2872-81. PubMed ID: 18843033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
